JP2018027929A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018027929A5 JP2018027929A5 JP2017026907A JP2017026907A JP2018027929A5 JP 2018027929 A5 JP2018027929 A5 JP 2018027929A5 JP 2017026907 A JP2017026907 A JP 2017026907A JP 2017026907 A JP2017026907 A JP 2017026907A JP 2018027929 A5 JP2018027929 A5 JP 2018027929A5
- Authority
- JP
- Japan
- Prior art keywords
- strontium
- formulation
- formulation according
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 238000009472 formulation Methods 0.000 claims 23
- 229920000642 polymer Polymers 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 5
- 229960004308 acetylcysteine Drugs 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 229910052712 strontium Inorganic materials 0.000 claims 5
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000003251 Pruritus Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- -1 cationic strontium salts Chemical class 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 claims 2
- IATRAKWUXMZMIY-UHFFFAOYSA-N strontium oxide Chemical compound [O-2].[Sr+2] IATRAKWUXMZMIY-UHFFFAOYSA-N 0.000 claims 2
- UBXAKNTVXQMEAG-UHFFFAOYSA-L strontium sulfate Chemical compound [Sr+2].[O-]S([O-])(=O)=O UBXAKNTVXQMEAG-UHFFFAOYSA-L 0.000 claims 2
- ZLCOWUKVVFVVKA-WDSKDSINSA-N (2r)-3-[[(2r)-2-acetamido-2-carboxyethyl]disulfanyl]-2-aminopropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSSC[C@H](N)C(O)=O ZLCOWUKVVFVVKA-WDSKDSINSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- ZWZDILQREOBSST-UHFFFAOYSA-N [Sr].S Chemical compound [Sr].S ZWZDILQREOBSST-UHFFFAOYSA-N 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 229920006318 anionic polymer Polymers 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- QCNCAQHKMMAWSP-UHFFFAOYSA-N butanedioic acid;strontium Chemical compound [Sr].OC(=O)CCC(O)=O QCNCAQHKMMAWSP-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- HSPYGHDTVQJUDE-LURJTMIESA-N dacisteine Chemical compound CC(=O)N[C@H](C(O)=O)CSC(C)=O HSPYGHDTVQJUDE-LURJTMIESA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229960000633 dextran sulfate Drugs 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- MLCQLNYCRIEWMX-ZZMNMWMASA-L strontium (2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-olate Chemical compound [Sr+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] MLCQLNYCRIEWMX-ZZMNMWMASA-L 0.000 claims 1
- 229910000018 strontium carbonate Inorganic materials 0.000 claims 1
- 229940013553 strontium chloride Drugs 0.000 claims 1
- 229910001631 strontium chloride Inorganic materials 0.000 claims 1
- 229940047908 strontium chloride hexahydrate Drugs 0.000 claims 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims 1
- AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 claims 1
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 claims 1
- 229910001866 strontium hydroxide Inorganic materials 0.000 claims 1
- 159000000008 strontium salts Chemical class 0.000 claims 1
- XUBXWWLLZIPPHW-DFWYDOINSA-L strontium;(2s)-2-aminopentanedioate Chemical compound [Sr+2].[O-]C(=O)[C@@H](N)CCC([O-])=O XUBXWWLLZIPPHW-DFWYDOINSA-L 0.000 claims 1
- CCUZKVDGQHXAFK-UHFFFAOYSA-L strontium;2-hydroxypropanoate Chemical compound [Sr+2].CC(O)C([O-])=O.CC(O)C([O-])=O CCUZKVDGQHXAFK-UHFFFAOYSA-L 0.000 claims 1
- GBIVDQYBCRNZBY-UHFFFAOYSA-L strontium;2-oxopentanedioate Chemical compound [Sr+2].[O-]C(=O)CCC(=O)C([O-])=O GBIVDQYBCRNZBY-UHFFFAOYSA-L 0.000 claims 1
- YXAMJFINXWQMCB-UHFFFAOYSA-L strontium;2-oxopropanoate Chemical compound [Sr+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O YXAMJFINXWQMCB-UHFFFAOYSA-L 0.000 claims 1
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 claims 1
- LVZZABGEQTZXHP-UHFFFAOYSA-L strontium;propanedioate Chemical compound [Sr+2].[O-]C(=O)CC([O-])=O LVZZABGEQTZXHP-UHFFFAOYSA-L 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 229940022036 threonate Drugs 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- QGAPCDHPGCYAKM-UHFFFAOYSA-H tristrontium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QGAPCDHPGCYAKM-UHFFFAOYSA-H 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087003A JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208249P | 2015-08-21 | 2015-08-21 | |
| US15/239,171 US20170049807A1 (en) | 2015-08-21 | 2016-08-17 | Strontium based compositions and formulations for pain, pruritus, and inflammation |
| US15/239,171 | 2016-08-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087003A Division JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018027929A JP2018027929A (ja) | 2018-02-22 |
| JP2018027929A5 true JP2018027929A5 (enExample) | 2020-03-05 |
| JP7103752B2 JP7103752B2 (ja) | 2022-07-20 |
Family
ID=58157450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017026907A Active JP7103752B2 (ja) | 2015-08-21 | 2017-02-16 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
| JP2021087003A Active JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087003A Active JP7322094B2 (ja) | 2015-08-21 | 2021-05-24 | 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170049807A1 (enExample) |
| JP (2) | JP7103752B2 (enExample) |
| AU (2) | AU2017201085B2 (enExample) |
| ES (1) | ES2925861T3 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3172684B2 (ja) | 1996-12-03 | 2001-06-04 | ワイケイケイアーキテクチュラルプロダクツ株式会社 | 断熱サッシ |
| JP6163633B2 (ja) | 2012-03-21 | 2017-07-19 | コスメダーム バイオサイエンス， インコーポレイテッド | 疼痛、そう痒および炎症を処置するために局所的に投与されるストロンチウム含有複合体 |
| US11235002B2 (en) | 2015-08-21 | 2022-02-01 | Galleon Labs Llc | Strontium based compositions and formulations for pain, pruritus, and inflammation |
| WO2019210035A1 (en) * | 2018-04-25 | 2019-10-31 | Horizon Orphan Llc | Methods of treating excitotoxicity disorders |
| WO2022173813A1 (en) * | 2021-02-09 | 2022-08-18 | The Regents Of The University Of California | Improved bhb-citrate formulations for promoting health |
| CN113041487B (zh) * | 2021-04-23 | 2025-01-28 | 佳木斯大学 | 一种90锶敷贴器治疗装置 |
| CN114452297B (zh) * | 2021-12-30 | 2024-03-12 | 河南大新药业有限公司 | 一种治疗皮炎的药物制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051609A (en) * | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
| AU618517B2 (en) * | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
| US5716625A (en) * | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| AU783104B2 (en) * | 1999-09-14 | 2005-09-22 | Tepha, Inc. | Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| NO20014746D0 (no) * | 2001-09-28 | 2001-09-28 | Clas M Kjoelberg | Smertelindrende middel |
| JP6163633B2 (ja) * | 2012-03-21 | 2017-07-19 | コスメダーム バイオサイエンス， インコーポレイテッド | 疼痛、そう痒および炎症を処置するために局所的に投与されるストロンチウム含有複合体 |
-
2016
- 2016-08-17 US US15/239,171 patent/US20170049807A1/en not_active Abandoned
-
2017
- 2017-02-16 JP JP2017026907A patent/JP7103752B2/ja active Active
- 2017-02-16 ES ES17156555T patent/ES2925861T3/es active Active
- 2017-02-17 AU AU2017201085A patent/AU2017201085B2/en active Active
-
2021
- 2021-05-24 JP JP2021087003A patent/JP7322094B2/ja active Active
-
2023
- 2023-08-31 AU AU2023222925A patent/AU2023222925B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510943A5 (enExample) | ||
| JP6257604B2 (ja) | アポモルヒネと有機酸とを含む組成物およびその使用 | |
| HRP20200366T1 (hr) | Kontinuirana primjena l-dopa, inhibitora dopa-dekarboksilaze, inhibitora katekol-o-metil-transferaze i njihovih pripravaka | |
| TWI430814B (zh) | 含有非聚集鋅奈米顆粒之口腔組成物 | |
| JP5627854B2 (ja) | 胃の逆流抵抗性投薬形態 | |
| BR112012024683B1 (pt) | Composição oral | |
| WO2008069941A2 (en) | Modified release ibuprofen solid oral dosage form | |
| JP2010529018A5 (ja) | 医薬組成物、および医薬錠剤 | |
| CN115089556A (zh) | 利那洛肽的延迟释放组合物 | |
| RU2016135952A (ru) | Композиции ингибитора дофа-декарбоксилазы | |
| JP2023530235A5 (enExample) | ||
| JP2022179727A (ja) | リナクロチドの改変または標的放出製剤 | |
| US20250108026A1 (en) | Droxidopa compositions and methods | |
| JP2015518038A5 (enExample) | ||
| US20100129448A1 (en) | Topical hydrogel composition | |
| RU2016121401A (ru) | Устойчивые при хранении лиофилизованные составы трипептидов | |
| AU2014348470A1 (en) | Solid compositions of triglycerides and uses thereof | |
| CN101961312A (zh) | 一种注射用硫辛酸组合物 | |
| JP2020196677A (ja) | 錠剤の製造方法 | |
| CN106667944A (zh) | 含有前列腺素类药物的缓释制剂 | |
| JP2010540448A5 (enExample) | ||
| Paroha et al. | Physicochemical interaction of naproxen with aluminium hydroxide and its effect on dissolution | |
| JP2005298373A (ja) | 吸水性アミノ酸含有糖衣錠剤 | |
| JP5572110B2 (ja) | 粘膜の疾患および障害の予防および処置のための液体製剤 | |
| WO2016114017A1 (ja) | オルメサルタンメドキソミルを含有するフィルムコーティング錠剤 |